This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Histone deacetylase 1 (HDAC1); HDAC3	*In vitro* and mouse studies have identified inhibitors selective for HDAC1 and HDAC3 that could help treat cancer. *In vitro*, the most potent *N*-hydroxycinnamamide–based derivatives had low nanomolar potency against HDAC1 and HDAC3 and low micromolar potency against other HDACs. In a panel of solid and hematological tumor cells, the most potent and selective dual inhibitor blocked proliferation better than a nonselective HDAC inhibitor. In mice with subcutaneous lymphoma xenografts, the most potent dual inhibitor decreased tumor growth more than a nonselective inhibitor. Next steps include additional structural optimization of the compounds. *SciBX* 7(18); doi:10.1038/scibx.2014.519 Published online May 8, 2014	Patent application filed; available for licensing	Li, X. *et al. J. Med. Chem.*; published online April 2, 2014; doi:10.1021/jm401877m **Contact:** Wenfang Xu, Shandong University, Shandong, China e-mail: xuwenf@gmail.com **Contact:** Yingjie Zhang, same affiliation as above e-mail: zhangyingjie@sdu.edu.cn